The arachidonate 5-lipoxygenase activating protein (ALOX5AP, also called FLAP — 5-Lipoxygenase Activating Protein) is an indispensable scaffold protein anchored in the nuclear and endoplasmic reticulum membranes of myeloid cells. Without FLAP, the enzyme 5-lipoxygenase cannot bind arachidonic acid efficiently enough to produce leukotrienes¹¹ leukotrienes
potent lipid mediators that drive inflammation in arterial walls, atherosclerotic plaques, and during thrombotic events. Pharmacological blockade of FLAP with compounds like MK-886 abolishes leukotriene synthesis entirely — making ALOX5AP one of the most druggable targets in the inflammatory pathway.

rs17222814 (designated SG13S114 in the original deCODE Genetics mapping work) is an intronic variant that serves as a tag for the HapB haplotype — a distinct four-marker ALOX5AP haplotype identified as an independent cardiovascular risk signal in Icelandic and UK populations. HapB is separate from the more widely studied HapA haplotype; the two tag different regulatory variations within ALOX5AP and show different population distributions and association patterns.

The Mechanism

FLAP sits at the membrane and presents arachidonic acid to 5-lipoxygenase (ALOX5), enabling the two-step oxidation of arachidonic acid to leukotriene A4 (LTA4). LTA4 is then either hydrolyzed to the potent neutrophil chemoattractant leukotriene B4 (LTB4)²² leukotriene B4 (LTB4)
acts on BLT1 and BLT2 receptors on neutrophils and macrophages; a major driver of neutrophil recruitment to atherosclerotic plaques, or conjugated with glutathione to form the cysteinyl leukotrienes (LTC4, LTD4, LTE4) that drive smooth muscle contraction in bronchi and vasculature.

In atherosclerosis, LTB4 recruits neutrophils and macrophages into vascular plaques, amplifies oxidative stress within the plaque microenvironment, and promotes the inflammatory signaling cascade that destabilizes fibrous caps — the proximate cause of acute MI and stroke. rs17222814 is intronic and does not directly change the FLAP protein sequence. As a haplotype tag, it marks a set of regulatory variants that may alter ALOX5AP expression levels or splicing efficiency in cardiovascular-relevant tissues, though the precise causal variant within the HapB haplotype block remains to be identified.

The Evidence

The foundational discovery came from deCODE Genetics (Helgadottir et al., Nature Genetics 2004)³³ deCODE Genetics (Helgadottir et al., Nature Genetics 2004)
whole-genome linkage mapping in Icelandic families followed by haplotype association in independent case-control samples from Iceland and the UK. Two distinct ALOX5AP haplotypes — HapA and HapB — each conferred approximately doubled risk of myocardial infarction. Crucially, stimulated neutrophils from MI patients carrying either haplotype produced more leukotriene B4 than those from controls, providing a direct mechanistic link between ALOX5AP variation and the leukotriene pathway in cardiovascular disease.

Replication in a Scottish stroke cohort (Helgadottir et al., AJHG 2005)⁴⁴ Replication in a Scottish stroke cohort (Helgadottir et al., AJHG 2005)
450 stroke cases and 710 controls from Aberdeenshire, independent of the Icelandic discovery cohort confirmed HapA's association with ischemic stroke (relative risk 1.36, p=0.007). HapB was overrepresented in male stroke patients, supporting the concept that the two haplotypes affect cardiovascular risk through partially distinct mechanisms. A Swedish stroke registry study (Lovkvist et al., EJHG 2008)⁵⁵ Swedish stroke registry study (Lovkvist et al., EJHG 2008)
932 ischemic stroke patients and 396 controls from a population-based register directly examined rs17222814, finding that the A allele was associated with stroke risk specifically in non-hypertensive individuals (OR=1.82, 95% CI 1.21–2.74; p=0.0039), though this did not survive correction for multiple testing.

In an Italian angiography-based CAD study (Girelli et al., EJHG 2007) of 1,431 patients, HapB was significantly overrepresented in patients with angiographically confirmed coronary artery disease⁶⁶ HapB was significantly overrepresented in patients with angiographically confirmed coronary artery disease
OR=1.67, 95% CI 1.04–2.67; p=0.032, suggesting a role in atheroma development rather than purely thrombotic events.

The evidence is not uniformly positive. A nested case-control study within the Physicians' Health Study (Zee et al., Stroke 2006)⁷⁷ nested case-control study within the Physicians' Health Study (Zee et al., Stroke 2006)
600 MI/stroke cases and 600 matched controls from a US male physician cohort found no significant association of HapB with MI or stroke (HapB OR for MI=0.62, p=0.08). A UK functional study (Maznyczka et al., Clin Sci 2007)⁸⁸ UK functional study (Maznyczka et al., Clin Sci 2007)
59 healthy subjects stratified by haplotype status, measuring LTB4 from isolated neutrophils found no difference in stimulated LTB4 production between HapA, HapB, and non-carrier groups, suggesting that if the haplotypes increase cardiovascular risk, they may do so through context-dependent mechanisms (e.g., within inflamed arterial tissue, under pro-inflammatory stimulation) rather than via a simple constitutive increase in leukotriene output. Overall, the effect of HapB is real but modest and population-heterogeneous — more robustly detected in European populations of Northern and Southern European ancestry, less consistently in North American cohorts.

Practical Actions

The A allele of rs17222814 marks a modestly elevated leukotriene-pathway activation background. The most evidence-based intervention for leukotriene pathway-associated cardiovascular risk is the competitive substrate strategy: high-dose EPA from marine or algae sources competitively displaces arachidonic acid, reducing the amount of substrate available for FLAP-mediated leukotriene production. EPA-derived leukotrienes (leukotriene B5) are substantially weaker chemoattractants than the arachidonic-acid-derived LTB4, reducing net inflammatory signaling from the pathway.

Elevated high-sensitivity CRP (hsCRP) and LTB4 urinary metabolites (urinary LTE4) can be used to gauge baseline inflammatory tone and track response to dietary or supplemental interventions. For carriers who also smoke or have hypertension, the synergistic impact on arterial inflammation merits particular attention.

Interactions

HapB (tagged by rs17222814) and HapA (tagged by rs10507391 and related SNPs) are independent haplotypes within ALOX5AP and are not simply additive — individuals can carry alleles on both haplotype blocks simultaneously. The combined effect of carrying both haplotypes has not been formally quantified in a published compound-genotype analysis, but given both haplotypes increase leukotriene-pathway activity, an additive or synergistic effect is biologically plausible.

Within the leukotriene biosynthesis cascade, ALOX5AP variants interact with downstream gene variants in LTA4H (leukotriene A4 hydrolase) and ALOX5 promoter variants. The LTA4H gene has its own cardiovascular risk haplotype (HapK), and combined pathway burden across ALOX5AP, LTA4H, and ALOX5 may confer greater risk than any single variant alone.

Most genetic variants in the FADS1 gene cluster affect expression through intronic regulatory elements, but rs174546 operates through a distinct mechanism: it sits in the 3' untranslated region¹¹ 3' untranslated region
3'UTR — the section of an mRNA transcript downstream of the protein-coding sequence, critical for mRNA stability, translation efficiency, and microRNA-mediated regulation of the FADS1 transcript, where it alters a binding site for the microRNA miR-149-5p. When the T allele is present, the miRNA binds more effectively and suppresses FADS1 translation — reducing the amount of delta-5 desaturase²² delta-5 desaturase
FADS1 — the enzyme responsible for the final step converting DGLA to arachidonic acid in the omega-6 pathway and ETA to EPA in the omega-3 pathway protein that reaches the cell. The functional and clinical consequences mirror the broader FADS1 impairment seen across the haplotype: elevated precursor fatty acids, lower long-chain PUFA products, and measurably higher serum triglycerides.

The Mechanism

rs174546 creates a quantifiable drop in FADS1 mRNA output through a two-layer miRNA mechanism. In a luciferase reporter study³³ luciferase reporter study
Hermant et al. Identification of a functional FADS1 3'UTR variant associated with erythrocyte n-6 polyunsaturated fatty acids levels. J Clin Lipidol, 2018 of 540 subjects, the T allele haplotype reduced reporter gene activity by 30% at baseline. When miR-149-5p was co-expressed in the same system, the suppression deepened to 60% — and this amplified suppression was partially reversed when an miR-149-5p inhibitor was added, confirming that the miRNA is directly responsible for the allele-dependent effect.

Separately, the T allele interacts with miR-6728-3p in an in vivo Korean cohort⁴⁴ in vivo Korean cohort
Lee et al. Functional Impact of the FADS1 rs174546 Single Nucleotide Polymorphism on Serum Lipid Levels. Mol Nutr Food Res, 2024 of 8,842 adults, confirming that the 3'UTR functional effect is not limited to a single miRNA species or a single cell line model. The downstream result of reduced FADS1 protein — regardless of which miRNA mediates it — is the same: the delta-5 desaturation step slows, DGLA accumulates in the omega-6 arm, and ETA-to-EPA conversion in the omega-3 arm is rate-limited.

What distinguishes rs174546 from other FADS1 variants on the platform is the mechanistic specificity: we know exactly which part of the gene is disrupted, which miRNA binds the disrupted site, and by how much transcription falls. This makes it the most directly characterized FADS1 3'UTR variant studied to date.

The Evidence

The triglyceride signal from rs174546 is independently documented in 8,842 Korean participants. Lee et al. 2024⁵⁵ Lee et al. 2024 found that each T allele increases fasting serum triglycerides by 6.48 ± 1.84 mg/dL — an additive effect consistent with reduced FADS1-mediated LC-PUFA production altering VLDL assembly and postprandial triglyceride clearance. The effect is detectable on a standard fasting lipid panel, not just on specialized fatty acid measurements, placing rs174546 in the same clinical-consequence tier as the more-studied rs174547.

The FADS1 locus-wide evidence anchors the population context. The landmark InCHIANTI GWAS⁶⁶ landmark InCHIANTI GWAS
Tanaka et al. Genome-wide association study of plasma polyunsaturated fatty acids. PLoS Genet, 2009 demonstrated that the FADS1 haplotype (of which rs174546 is a member) accounts for 18.6% of all additive variance in circulating arachidonic acid — the largest explained variance for any common variant in PUFA metabolism. The CHARGE Consortium meta-analysis⁷⁷ CHARGE Consortium meta-analysis
Lemaitre et al. Genetic loci associated with plasma phospholipid n-3 fatty acids. PLoS Genet, 2011 across 8,866 participants confirmed that FADS1 cluster minor alleles predict lower circulating EPA (p=5×10⁻⁵⁸) and higher plant-sourced ALA (p=3×10⁻⁶⁴), validated across European, African, Chinese, and Hispanic ancestry groups.

Practical Actions

The 3'UTR mechanism does not change the practical implication of carrying the T allele: FADS1 produces less delta-5 desaturase protein, and the conversion of ALA to EPA slows accordingly. For CT heterozygotes, 1–2 g preformed EPA+DHA daily from marine or algae-based sources supplements the partially impaired conversion step. For TT homozygotes, where both alleles carry the T variant, the suppression is more complete — 2–4 g daily becomes appropriate, and relying solely on plant- sourced ALA (flaxseed, chia, walnuts) is insufficient because that ALA requires the impaired FADS1 step to reach EPA.

The triglyceride association adds a monitoring dimension. Because each T allele raises fasting triglycerides by approximately 6.5 mg/dL, TT homozygotes may carry a baseline elevation of ~13 mg/dL from this variant alone — detectable on a standard lipid panel when combined with dietary and metabolic factors.

Interactions

rs174546 is in high linkage disequilibrium with the established FADS1 haplotype that includes rs174541, rs174547, rs174548, rs174537, rs174553, and rs174561. Users carrying the T allele at rs174546 are likely to carry risk alleles at these linked sites on the same chromosomal segment. The variants tag the same underlying expression phenotype; their individual entries on the platform add resolution to different functional evidence layers — rs174546 provides the 3'UTR miRNA mechanism while rs174541 and rs174547 provide intronic regulatory and clinical lipid evidence.

The ELOVL2 variant rs17606561 encodes elongase 2, which converts EPA to DHA downstream of the FADS1 desaturation step. A user carrying both FADS1 T alleles (reduced ALA→EPA conversion) and an ELOVL2 impairment (reduced EPA→DHA conversion) faces sequential blocks in the omega-3 synthesis chain. For this combined genotype, DHA-targeted supplementation (≥500 mg DHA specifically, not just total EPA+DHA) addresses the downstream block that EPA supplementation alone would not reach.

Deep within the wall of every coronary artery, a molecular crane called TANGO1¹¹ TANGO1
Transport ANd Golgi Organization protein 1, encoded by the MIA3 gene on chromosome 1q41 performs a task that conventional COPII vesicles cannot: loading oversized collagen fibers — rigid triple-helical rods far too large for standard secretory vesicles — onto expanding membrane carriers for export from the endoplasmic reticulum (ER) to the extracellular matrix. The rs17465637 variant, nestled in intron 4 of MIA3, is one of the earliest and most robustly replicated GWAS hits for coronary artery disease (CAD). It was discovered by Samani et al. in 2007²² Samani et al. in 2007
WTCCC and German Myocardial Infarction Family Study combined analysis and has since been confirmed in cohorts spanning Europe, North America, East Asia, and South Asia.

The Mechanism

MIA3/TANGO1 sits at ER exit sites (ERES)³³ ER exit sites (ERES)
specialized membrane domains where secretory cargo is loaded into transport carriers and assembles into rings that enclose COPII coat proteins, creating a sub-compartment dedicated to packaging and exporting fibrillar collagens — including collagens I, II, III, IV, VII, and IX, and apolipoprotein B. Its SH3-like domain in the ER lumen binds collagens via the collagen chaperone HSP47; its cytoplasmic proline-rich domain (PRD) coordinates with the COPII machinery to initiate tubular carriers large enough for bulky cargo.

In the vascular wall, this matters in two distinct ways. First, MIA3 controls the mechanical integrity of the arterial wall by governing collagen secretion in smooth muscle cells and fibroblasts — reduced MIA3 function impairs the structural collagen scaffold that keeps plaques stable. Second, and paradoxically, MIA3 expression is elevated in proliferative vascular smooth muscle cells (VSMCs)⁴⁴ MIA3 expression is elevated in proliferative vascular smooth muscle cells (VSMCs)
Frontiers in Endocrinology, 2021, and knockdown of MIA3 reduces VSMC proliferation, migration, and inflammation. This dual role — structural collagen support vs. pro-proliferative signaling — explains why altered MIA3 expression at either extreme can promote atherosclerosis: too little disrupts plaque stability, too much accelerates neointimal thickening and luminal narrowing.

The rs17465637 variant lies in an intron and does not change the protein directly. Its effect is presumed to be regulatory — altering MIA3 splicing efficiency, transcription factor binding, or expression level in vascular tissues — but the precise molecular mechanism remains under investigation. A parallel molecular network has been characterized: ADTRP (Androgen-Dependent TFPI-Regulating Protein)⁵⁵ ADTRP (Androgen-Dependent TFPI-Regulating Protein)
another CAD GWAS locus on chromosome 6 positively regulates MIA3/TANGO1 expression through a PIK3R3 → AKT signaling cascade, linking androgen signaling, coagulation regulation, and collagen trafficking in endothelial cells — the same cells where monocyte adhesion initiates atherosclerotic plaque formation.

The Evidence

The evidence for rs17465637 is unusually robust for a GWAS intronic variant. The original discovery by Samani et al. (2007)⁶⁶ Samani et al. (2007)
Genome-wide association analysis of coronary artery disease, Nature Genetics in a combined analysis of the Wellcome Trust Case Control Consortium and German MI Family Study identified the C allele with OR 1.20 (95% CI 1.12–1.30) for CAD in Europeans. This was replicated in the American Caucasian Cleveland Genebank⁷⁷ American Caucasian Cleveland Genebank
PMC3115468, where the A allele (absence of the risk C allele) showed a protective effect of OR 0.75 (95% CI 0.62–0.91, P=0.003) against myocardial infarction.

Trans-ethnic replication is particularly compelling. A 2013 meta-analysis⁸⁸ A 2013 meta-analysis
PMID 24125424 of five Asian cohorts totaling 7,263 CAD patients and 8,347 controls confirmed OR 1.11 (P=4.97×10⁻⁵), formally establishing rs17465637 as a cross-ancestry CAD risk locus. A prospective follow-up study showed that the C allele predicted subsequent cardiovascular events⁹⁹ the C allele predicted subsequent cardiovascular events
PMID 21984477 not only in healthy controls, but also in patients with established CAD — suggesting ongoing biological risk rather than a one-time susceptibility signal.

One Pakistani study reported an additional finding: each C allele was associated with a 10.2 mg/dL increase in serum triglycerides¹⁰¹⁰ each C allele was associated with a 10.2 mg/dL increase in serum triglycerides
P=0.01, suggesting MIA3's role in ApoB trafficking from the ER may partially explain its cardiovascular effects through lipid metabolism, since ApoB is the structural protein of VLDL and LDL particles.

Practical Actions

Because rs17465637 is an intronic variant with an incompletely understood regulatory mechanism, there is no single gene-product intervention (such as supplementing an enzyme cofactor). The clinical value of knowing your genotype lies in risk stratification and targeted monitoring.

CC homozygotes carry approximately two copies of the risk allele and represent the majority genotype (~55% of Europeans). AC heterozygotes carry one copy. Only AA homozygotes (~7% of Europeans) carry the lower-risk, protective genotype. All non-AA genotypes benefit from earlier and more comprehensive cardiovascular monitoring — specifically coronary artery calcium (CAC) scoring as a sub-clinical atherosclerosis screen, and fasting lipid panels with attention to triglycerides given the documented lipid effect of the C allele.

The evidence that rs17465637 participates in a 27-locus genetic risk score that predicts statin benefit in primary prevention means that knowing your MIA3 genotype can help inform discussions about the timing of lipid-lowering therapy — particularly in the borderline-risk range where clinical guidelines allow physician discretion.

Interactions

MIA3/TANGO1 is regulated upstream by ADTRP (rs3825807 on chromosome 6p24), which activates MIA3 expression through a PIK3R3 → AKT cascade. Individuals carrying risk alleles at both loci may have compounded disruption of endothelial cell homeostasis and collagen trafficking. The literature does not yet provide quantitative compound-genotype OR estimates for rs17465637 and rs3825807 combined, so this interaction should be interpreted as pathway-level context rather than a confirmed additive risk calculation.

The collagen-secretion pathway connects MIA3 to rs12722 (COL5A1), which affects collagen V structure and arterial wall compliance. Reduced MIA3 function plus structurally altered collagen V could theoretically compound effects on arterial stiffness and plaque vulnerability, but direct interaction data are lacking in the current literature.

In 1990, Kenneth Blum and Ernest Noble published a landmark paper in JAMA¹¹ landmark paper in JAMA
Blum K, Noble EP et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA, 1990 linking a genetic marker near the dopamine D2 receptor gene to severe alcoholism. That marker, called TaqIA, became one of the most studied polymorphisms in behavioral genetics. Over three decades later, we know it affects far more than alcohol: this single nucleotide change influences how densely your brain populates its reward circuits with D2 dopamine receptors, shaping everything from how you learn from mistakes to how vulnerable you are to addictive behaviors.

What makes TaqIA unusual is a case of mistaken genomic identity. For years it was attributed to the DRD2 gene itself. In 2004, Neville and colleagues²² Neville and colleagues
Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat, 2004 discovered that the variant actually sits in exon 8 of an adjacent gene called ANKK1 (ankyrin repeat and kinase domain containing 1), which encodes a serine/threonine kinase³³ serine/threonine kinase
A type of enzyme that modifies proteins by adding phosphate groups to serine or threonine amino acids, regulating cell signaling pathways. Despite living in ANKK1's coding region, TaqIA's primary impact appears to be on D2 receptor expression in the striatum — the brain's reward hub.

The Mechanism

The A allele (historically called A1) causes a glutamic acid-to-lysine substitution at position 713 of the ANKK1 protein, within its eleventh ankyrin repeat⁴⁴ ankyrin repeat
Ankyrin repeats are structural motifs that mediate protein-protein interactions. They are found in many signaling proteins and help assemble molecular complexes. While this change doesn't destroy ANKK1's kinase activity, it may alter its substrate-binding specificity. Through mechanisms still being clarified, the A1 allele is associated with reduced D2 dopamine receptor density in the striatum⁵⁵ striatum
The striatum is a cluster of interconnected nuclei (caudate and putamen) deep in the brain that serves as the main input hub of the basal ganglia. It is central to reward processing, habit formation, and motor control.

A 2016 meta-analysis of PET imaging studies⁶⁶ 2016 meta-analysis of PET imaging studies
Smith CT et al. Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies. Transl Psychiatry, 2016 pooling five studies with 194 healthy participants confirmed that A1 carriers have significantly lower striatal D2 receptor binding (weighted standardized mean difference -0.57, 95% CI -0.87 to -0.27, p = 0.0002). This variant explains approximately 7% of the variance in striatal D2 receptor availability.

Fewer D2 receptors means the brain's reward system is less sensitive to dopamine. To achieve the same subjective sense of reward or satisfaction, A1 carriers may need more intense or more frequent stimulation — a concept Blum termed "reward deficiency syndrome"⁷⁷ Blum termed "reward deficiency syndrome"
Blum K et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs, 2000.

The Evidence

Addiction and substance use. The most replicated finding is the association with alcohol dependence. A 2013 meta-analysis of 61 studies⁸⁸ 2013 meta-analysis of 61 studies
Wang F et al. A large-scale meta-analysis of the association between the ANKK1/DRD2 Taq1A polymorphism and alcohol dependence. Hum Genet, 2013 covering 18,730 participants found a significant association (allelic OR 1.19, genotypic OR 1.24). The effect was consistent in European populations and remained stable after correction for publication bias. Associations with smoking have also been reported, with A1 carriers showing higher smoking rates (pooled OR 1.50 across multiple studies).

Reward processing and learning. In an influential fMRI study⁹⁹ fMRI study
Jocham G et al. Dopamine DRD2 polymorphism alters reversal learning and associated neural activity. J Neurosci, 2009, A1 carriers showed impaired reversal learning — they were worse at switching behavior after feedback changed, and had altered neural responses in the rostral cingulate zone. A 2008 Science paper by Stice and colleagues¹⁰¹⁰ 2008 Science paper by Stice and colleagues
Stice E et al. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science, 2008 demonstrated that among A1 carriers, higher BMI correlated with progressively blunted striatal activation during food consumption — suggesting a feed-forward cycle where reduced reward sensitivity drives compensatory overeating.

ADHD and attention. A meta-analysis of 11 studies¹¹¹¹ meta-analysis of 11 studies
Pan Y et al. Association between ANKK1 rs1800497 polymorphism of DRD2 gene and ADHD: a meta-analysis. Neurosci Lett, 2015 with 3,286 participants found the A1 allele associated with ADHD risk (OR 1.79, 95% CI 1.07-2.98 in the dominant model), though the effect was strongest in African populations and less consistent in European and Asian samples.

Functional confirmation. A 2023 Biological Psychiatry study¹²¹² 2023 Biological Psychiatry study
Montalban E et al. The addiction-susceptibility TaqIA/Ankk1 controls reward and metabolism through D2 receptor-expressing neurons. Biol Psychiatry, 2023 using a mouse model confirmed that ANKK1 is enriched in striatal D2R-expressing neurons, and that loss of ANKK1 function leads to alterations in learning, impulsivity, and body metabolism — providing direct causal evidence for the gene's role in reward circuitry.

Practical Implications

The actionable insight for A1 carriers centers on supporting dopamine production naturally and being aware of reward-seeking tendencies. The amino acid L-tyrosine¹³¹³ L-tyrosine
The direct biochemical precursor to dopamine. Tyrosine is converted to L-DOPA by tyrosine hydroxylase, then to dopamine by DOPA decarboxylase is the rate-limiting precursor for dopamine synthesis. Ensuring adequate tyrosine intake through protein-rich foods or supplementation may help maintain dopamine tone. Iron and vitamin D are cofactors in dopamine synthesis pathways — iron is required by tyrosine hydroxylase, and vitamin D receptors are expressed in dopamine-producing neurons.

Regular physical exercise is one of the most well-documented ways to upregulate D2 receptor expression naturally. Structured reward environments — breaking large goals into smaller milestones — can help compensate for reduced reward sensitivity. Perhaps most importantly, A1 carriers benefit from understanding their heightened vulnerability to addictive patterns, whether with substances, gambling, or compulsive eating.

Interactions

The COMT gene (rs4680, Val158Met) regulates dopamine breakdown in the prefrontal cortex. Individuals who carry both the ANKK1 A1 allele (reduced D2 receptor density) and COMT Met/Met genotype (slower dopamine clearance) may experience a complex dopamine imbalance: excess prefrontal dopamine coupled with reduced striatal reward sensitivity. Studies of disordered eating have found significant DRD2 x COMT gene-gene interactions affecting eating behavior and body weight regulation. The combined effect may amplify reward-seeking behavior beyond what either variant alone would predict.

NEGR1 (Neuronal Growth Regulator 1) encodes a cell-adhesion molecule expressed primarily in the hypothalamus, the brain region that acts as the body's central thermostat for hunger, satiety, and energy expenditure. ¹¹ NEGR1 belongs to the IgLON family of immunoglobulin-domain cell adhesion molecules that regulate neurite outgrowth and synapse formation The rs1841499 variant sits within the NEGR1 locus on chromosome 1p31.1 and was identified as a novel shared risk locus between migraine and type 2 diabetes in a large cross-trait GWAS meta-analysis.

The Mechanism

NEGR1 promotes cell-cell adhesion and neurite growth in hypothalamic neurons that control food intake. The protein is cleaved by the protease ADAM10, activating FGFR2 signaling and promoting neuronal spine plasticity. When NEGR1 function is reduced, hypothalamic circuits governing appetite become dysregulated, leading to increased food intake and body weight gain. ²² In mouse models, NEGR1 knockout leads to increased adiposity, decreased lean mass, and pre-diabetic metabolic changes

The variant's effect on both migraine and metabolic disease likely stems from NEGR1's dual role: it shapes hypothalamic neural architecture (affecting energy balance) while also modulating monoaminergic neurotransmission (dopamine and serotonin pathways implicated in migraine). NEGR1-deficient mice show altered dopamine release in the striatum and upregulation of dopamine and serotonin transporters.

The Evidence

The cross-trait GWAS meta-analysis³³ cross-trait GWAS meta-analysis
Siewert-Rocks et al. Genetic Overlap Analysis Identifies a Shared Etiology between Migraine and Headache with Type 2 Diabetes. Genes, 2022 identified rs1841499 at the NEGR1 locus as one of 23 novel shared loci between migraine and type 2 diabetes (P = 2.86 x 10^-8), with concordant protective effects for both traits (migraine OR 0.98, T2D OR 0.97 for the A allele).

NEGR1 was originally identified as an obesity gene through large-scale GWAS. Functional studies in mice⁴⁴ Functional studies in mice
Lee et al. Functional Inactivation of the Genome-Wide Association Study Obesity Gene NEGR1 in Mice. PLOS ONE, 2012 confirmed that NEGR1 inactivation causes significant body mass changes. A rat hypothalamic study⁵⁵ rat hypothalamic study
Boender et al. The obesity-associated gene Negr1 regulates aspects of energy balance in rat hypothalamic areas. Physiol Genomics, 2014 demonstrated that decreased NEGR1 expression in periventricular hypothalamic areas increases body weight through increased food intake.

The C allele frequency varies dramatically across ancestries: ~38% in Europeans but only ~8% in East Asians and ~47% in Africans, which may contribute to population-level differences in obesity prevalence patterns.

Practical Actions

Carriers of the C allele have a genetically predisposed tendency toward increased appetite drive. While the per-allele effect is modest (consistent with typical GWAS obesity loci), it compounds with other appetite and metabolism variants. The dual migraine-metabolic connection suggests that metabolic interventions supporting stable blood glucose may benefit both conditions.

Interactions

NEGR1 operates in the same hypothalamic appetite-regulation network as other obesity GWAS genes including MC4R and FTO. The variant rs2815752, located ~60 kb upstream of NEGR1, is in the same GWAS locus and may tag partially overlapping regulatory elements. Carriers of risk alleles at multiple appetite-regulation loci may experience compounding effects on satiety signaling.

Endometriosis requires blood. Ectopic lesions — fragments of endometrial-like tissue that implant on the peritoneum, ovaries, and bowel — cannot grow beyond a few millimetres without recruiting their own vascular supply. VEGFR2 (vascular endothelial growth factor receptor 2)¹¹ VEGFR2 (vascular endothelial growth factor receptor 2)
Also called KDR (kinase insert domain receptor) or FLK1; the primary tyrosine kinase receptor through which VEGF-A drives endothelial proliferation, survival, migration, and tubular morphogenesis is the central throttle on this neovascularization. Variants in its regulatory region that subtly raise VEGFR2 expression — or lower the signaling threshold — make it easier for ectopic tissue to establish a durable blood supply and survive.

rs1903068 sits approximately 17 kilobases upstream of the KDR gene on chromosome 4q12. It is intergenic and carries no protein-coding consequence; its effect is regulatory — it lies in a region implicated in long-range transcriptional control of KDR expression. The nearby variant rs17773813 (492 bp away in the same regulatory zone) was the lead GWAS signal for this locus in the original Icelandic discovery cohort, and rs1903068 tags the same haplotype block.

The Mechanism

[KDR encodes VEGFR2 | A type III receptor tyrosine kinase; upon VEGF-A or VEGF-C binding, it autophosphorylates and activates the PI3K–AKT and MAPK–ERK cascades driving endothelial proliferation, survival, and tube formation], the dominant mediator of angiogenic signalling in endothelial cells. In women with endometriosis, peritoneal fluid and ectopic lesions contain substantially elevated VEGF concentrations, creating a permissive neovascular environment. The upstream regulatory variants at the KDR locus likely modulate baseline VEGFR2 expression in endometrial and endothelial cells — even modest upregulation of receptor density amplifies the response to the elevated VEGF milieu, allowing nascent ectopic implants to vascularise more efficiently and progress to established lesions.

The effect size is larger in moderate-to-severe (Stage III/IV) endometriosis than in minimal-to-mild disease, consistent with an angiogenesis-dependent mechanism: deep infiltrating lesions and endometriomas require more extensive neovascularisation than superficial peritoneal implants, making the VEGFR2 pathway a proportionally greater determinant of whether disease progresses to advanced stages.

The Evidence

The strongest genomic evidence for the KDR/4q12 locus comes from two large GWAS:

Steinthorsdottir et al. (2016)²² Steinthorsdottir et al. (2016)
Common variants upstream of KDR encoding VEGFR2 and in TTC39B associate with endometriosis. Nature Communications 7:12350 conducted a whole-genome sequencing–based GWAS of 1,840 Icelandic endometriosis cases and 129,016 controls, identifying rs17773813[G] upstream of KDR at genome-wide significance (OR = 1.28, P = 3.8 × 10⁻¹¹). Crucially, the variant stratified disease severity — the G allele was significantly enriched in moderate-to-severe versus minimal-to-mild cases (P = 0.0046), making it one of the few endometriosis loci with an explicit severity-dependency signal.

Rahmioglu et al. (2023)³³ Rahmioglu et al. (2023)
The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nature Genetics 55:423–436 meta-analysed data from 60,674 endometriosis cases and 701,926 controls — the largest endometriosis genetics study to date. Among the 42 genome-wide significant loci identified, KDR/4q12 was one of six showing non-overlapping confidence intervals between stage I/II and stage III/IV analyses, confirming that the locus exerts its largest effects in advanced disease. rs1903068 tags this same KDR regulatory haplotype.

Practical Actions

The KDR pathway is directly targetable by dietary polyphenols. Epigallocatechin-3-gallate (EGCG), the primary catechin in green tea, has well-characterised anti-angiogenic effects specific to the VEGFR2 pathway. Xu et al. (2011)⁴⁴ Xu et al. (2011)
Fertil Steril 96:1021–28 demonstrated that EGCG selectively suppresses VEGFC and VEGFR2 expression in experimental endometriosis, inhibiting microvessel formation in ectopic implants in vivo — with VEGFC supplementation reversing the inhibitory effect, confirming pathway specificity. Wang et al. (2013)⁵⁵ Wang et al. (2013)
Angiogenesis 16:59–69 showed a prodrug form of EGCG with enhanced bioavailability significantly reduced lesion size and vascular density over 4 weeks in a mouse model.

Resveratrol (found in red grape skin, blueberries, and dark chocolate) acts through complementary anti-angiogenic mechanisms: Madanes et al. (2022)⁶⁶ Madanes et al. (2022)
Reprod Biomed Online 44:891–901 demonstrated dose-dependent reduction in VEGF mRNA and angiopoietin-1 (Ang-1) expression in endometriotic cell cultures alongside reduced cell migration and viability.

For G allele carriers — particularly GG homozygotes — supporting awareness of endometriosis symptoms and ensuring early specialist evaluation if symptoms arise is the most clinically meaningful action from this result.

Interactions

rs17773813 (KDR upstream region): The lead Icelandic GWAS variant is at the same regulatory locus, 492 bp from rs1903068. These two variants are likely in strong LD and tag the same biological effect. Carrying G at rs1903068 is equivalent to tagging the rs17773813-G haplotype.

rs12700667 (7p15.2 / HOXA10-HOXA11 region): The most robustly replicated endometriosis locus acts through a different pathway (HOX gene regulation of endometrial development). Women carrying risk alleles at both KDR/4q12 and 7p15.2 would accumulate risk through distinct biological axes — angiogenesis competence and endometrial developmental programming. No formal gene-gene interaction paper exists, but additive risk is biologically plausible.

For a supervisor compound action proposal: women carrying the G risk allele at rs1903068 (KDR angiogenesis locus) who also carry the A risk allele at rs12700667 (HOX developmental locus) represent a biologically coherent high-risk combination for moderate-to-severe endometriosis. The combined recommendation would be earlier specialist evaluation, proactive disease-severity monitoring, and supplementation with EGCG to target the VEGFR2 pathway that the KDR variant specifically sensitises. Evidence level: emerging for the combination (no published interaction paper); each locus is independently strong-to-established.

The MMAB gene encodes ATP:cob(I)alamin adenosyltransferase (ATR)¹¹ ATP:cob(I)alamin adenosyltransferase (ATR)
The enzyme that converts reduced cob(I)alamin to adenosylcobalamin (AdoCbl), the cofactor required by methylmalonyl-CoA mutase for propionate catabolism in mitochondria, a critical last step in the mitochondrial vitamin B12 processing pathway. When both copies of MMAB are non-functional, methylmalonyl-CoA cannot be converted to succinyl-CoA, and methylmalonic acid accumulates to toxic levels in blood, urine, and tissues — the condition known as methylmalonic aciduria cblB type²² methylmalonic aciduria cblB type
OMIM #251110; the 'cblB' designation refers to the complementation class originally defined by somatic cell fusion studies before the gene was identified. The variant at rs199971687 disrupts the splice acceptor site at the intron 3–exon 4 boundary of MMAB, destroying normal pre-mRNA processing and causing complete loss of functional ATR protein.

The Mechanism

The splice acceptor consensus sequence (AG at the 3′ end of each intron) is essential for the spliceosome to remove the intron and join exon 3 to exon 4. The c.291-1G>A and c.291-1G>T substitutions (both reported at rs199971687 on the coding/minus strand, appearing as C>T and C>A respectively on the plus strand in genome files) each destroy the invariant G of this AG dinucleotide. Functional studies on the G>A allele showed no normal mRNA transcripts at exon 4-containing sequences³³ no normal mRNA transcripts at exon 4-containing sequences
ClinVar VCV000219004, citing functional RNA analysis submitted by multiple clinical laboratories, confirming that the splice defect is complete rather than leaky.

The ATR enzyme functions as a homotrimer with three ATP-binding sites and two non-equivalent adenosylcobalamin-binding sites (Kd values of 0.55 µM and 8.4 µM). Forny et al. 2022⁴⁴ Forny et al. 2022
Forny P et al. Spectrum and characterization of bi-allelic variants in MMAB causing cblB-type methylmalonic aciduria. Hum Genet, 2022 showed that the propionate incorporation ratio — the ratio of propionate metabolism with and without added hydroxocobalamin — predicts both clinical cobalamin responsiveness and age of disease onset. Splice-site variants that eliminate mRNA entirely effectively produce a null allele; disease onset and responsiveness depends on what the second allele produces.

The Evidence

The two pathogenic alleles at this locus are both classified as Pathogenic in ClinVar: the G>A allele (ClinVar VCV000219004) carries criteria-provided review status with nine submitting laboratories including LabCorp, Invitae, Mayo Clinic, Baylor Genetics, and GeneDx. The G>T allele (ClinVar VCV001173991) was documented by the Baumgartner laboratory at the University Children's Hospital Zurich and reported in the Forny et al. 2022 case series.

Lerner-Ellis et al. 2006⁵⁵ Lerner-Ellis et al. 2006
Lerner-Ellis JP et al. Mutation and biochemical analysis of patients belonging to the cblB complementation class of vitamin B12-dependent methylmalonic aciduria. Mol Genet Metab, 2006 sequenced MMAB in 35 cblB patients and identified 19 mutations including four splice-site variants. The most common European pathogenic allele is p.(Arg186Trp) at c.556C>T, accounting for 29–33% of European cblB alleles; rs199971687 is a rare allele that has been observed primarily in individual case reports.

cblB-type MMA has a birth prevalence of approximately 1 in 159,614 in the US⁶⁶ 1 in 159,614 in the US
Manoli I et al., GeneReviews, Isolated Methylmalonic Acidemia, NCBI Bookshelf NBK1231, 2022, with higher rates in the Middle East, North Africa, and parts of East Asia due to founder effects and consanguinity. This makes obligate carriers — individuals with one loss-of-function MMAB allele — far more common than affected individuals, with an estimated carrier frequency of roughly 1 in 200 in European populations.

Practical Actions

For carriers (CT genotype): Carriers have one functional MMAB allele producing sufficient ATR enzyme to handle normal propionate metabolism. No metabolic symptoms occur in heterozygous carriers, and no dietary or supplementation changes are needed for the carrier's own health. The clinical significance of carrier status is entirely in the domain of family planning: if both parents carry a pathogenic MMAB allele, each pregnancy carries a 25% risk of producing an affected child.

For affected individuals (TT or homozygous/compound heterozygous for any two MMAB loss-of-function alleles): Treatment depends on cobalamin responsiveness. Approximately 40–50% of cblB patients show at least partial responsiveness to pharmacological-dose hydroxocobalamin⁷⁷ hydroxocobalamin
The natural, non-cyano form of B12; preferred over cyanocobalamin for cobalamin metabolism disorders because it is more efficiently retained and distributed to mitochondria. Standard assessment involves 1 mg hydroxocobalamin intramuscularly daily for 3–5 days; a reduction in urinary methylmalonic acid by >50% defines responsiveness. All cblB patients, regardless of responsiveness, require protein-restricted diet, emergency metabolic protocols during illness, and regular monitoring of methylmalonic acid, ammonia, renal function, and neurological status.

Interactions

MMAB loss-of-function sits at a node where several B12 processing pathways converge. AdoCbl is the exclusive cofactor for methylmalonyl-CoA mutase; without it, propionate catabolism halts regardless of circulating B12 levels. The downstream biochemical consequences — elevated propionylcarnitine, methylmalonic acid, and homocysteine — connect MMAB deficiency to the folate-methylation cycle. Carriers of common MTHFR variants (rs1801133) already have moderately elevated homocysteine; an MMAB carrier parent in a family with known cblB history should be aware of this compounding possibility in an affected child who has biallelic MMAB loss.

For genetic counseling purposes, rs199971687 should be interpreted in the context of the second MMAB allele. Many compound heterozygous cblB patients carry this splice-site allele on one chromosome and a missense allele (such as p.Arg186Trp) on the other. In those combinations, cobalamin responsiveness is determined by which allele retains more residual function — typically the missense allele.

Your immune system maintains a delicate balance between fighting threats and attacking your own body. At the center of this balance sits A20, a protein encoded by the TNFAIP3 gene¹¹ A20, a protein encoded by the TNFAIP3 gene
TNFAIP3 stands for TNF Alpha Induced Protein 3; A20 is its common protein name that functions as a master brake on inflammation. The F127C variant (rs2230926) weakens this brake, and the consequences ripple through your immune system — from joints to gut lining to salivary glands.

The Mechanism

A20 is a ubiquitin-editing enzyme²² ubiquitin-editing enzyme
Ubiquitin is a small protein tag that cells attach to other proteins to control their fate — marking them for destruction, altering their activity, or changing their interactions with a remarkable dual function. Its N-terminal OTU domain strips K63-linked ubiquitin chains³³ N-terminal OTU domain strips K63-linked ubiquitin chains
K63 ubiquitin chains activate inflammatory signaling proteins; removing them shuts the signal down from signaling proteins like RIP1, while its C-terminal zinc finger domain adds K48-linked chains⁴⁴ C-terminal zinc finger domain adds K48-linked chains
K48 ubiquitin chains tag proteins for destruction by the proteasome that target them for proteasomal degradation. This two-step process — deactivate then destroy — efficiently terminates NF-kB signaling after it has served its purpose.

When TNF-alpha or bacterial products trigger inflammation, NF-kB activates and rapidly induces A20 expression as a negative feedback loop⁵⁵ rapidly induces A20 expression as a negative feedback loop
A20's own promoter contains NF-kB binding sites, so inflammation triggers its own off-switch. The F127C variant sits in the OTU deubiquitinase domain, and the cysteine substitution reduces A20's ability to inhibit TNF-induced NF-kB activation⁶⁶ cysteine substitution reduces A20's ability to inhibit TNF-induced NF-kB activation
Functional studies show the Cys127 variant is less effective at suppressing NF-kB than the normal Phe127 form. The result: inflammatory signals persist longer and reach higher intensity than they should.

Beyond immune signaling, A20 plays a direct role in gut barrier integrity. TNFAIP3 maintains intestinal epithelial tight junctions⁷⁷ TNFAIP3 maintains intestinal epithelial tight junctions
A20 deubiquitinates occludin, a key tight junction protein, preventing its degradation and maintaining barrier function by regulating the ubiquitination of occludin. Mice lacking TNFAIP3 show increased intestinal permeability, while overexpression protects against barrier breakdown — directly linking A20 function to gut health.

The Evidence

The F127C variant has been associated with a striking breadth of autoimmune conditions. A genome-wide association study of 1,239 SLE cases⁸⁸ genome-wide association study of 1,239 SLE cases
Study included 1,629 controls of European ancestry found rs2230926 independently associated with systemic lupus erythematosus (OR 2.0, 95% CI 1.4-3.0). Meta-analysis of 18,501 SLE patients and 30,435 controls⁹⁹ Meta-analysis of 18,501 SLE patients and 30,435 controls
Analysis across 23 studies from 20 publications confirmed the association in both Europeans (OR 2.25, P<10^-9) and Asians (OR 1.9, P=8.6x10^-11). In the Japanese population specifically, the odds ratio was 1.92 (95% CI 1.53-2.41)¹⁰¹⁰ odds ratio was 1.92 (95% CI 1.53-2.41).

For rheumatoid arthritis, a meta-analysis of 21 case-control studies¹¹¹¹ meta-analysis of 21 case-control studies
Included stratification by ethnicity showing significant effects in Asian populations found rs2230926 increases risk with OR 1.39 (95% CI 1.11-1.72). A separate sequencing study across multiple autoimmune diseases¹²¹² sequencing study across multiple autoimmune diseases
Genotyped rs2230926 in 1,513 controls and patients with nine different autoimmune conditions demonstrated significant associations with Sjogren's syndrome (OR 3.38, P=0.038), Crohn's disease (OR 2.25, P=0.041), psoriasis (OR 2.17, P=0.037), and rheumatoid arthritis (OR 1.9, P=0.025).

The Sjogren's syndrome association is particularly notable. In a Greek cohort of 327 primary Sjogren's patients¹³¹³ In a Greek cohort of 327 primary Sjogren's patients
Compared against 448 healthy controls, the variant frequency was 8.0% versus 3.6% in controls (OR 2.3). Among patients who developed lymphoma before age 40, the frequency reached 18.2% (OR 6.0, 95% CI 1.8-19.8). Carriers showed elevated Bcl-XL expression — evidence of abnormal NF-kB activation providing a survival signal to B cells that can drive lymphoma.

The variant shows dramatic population stratification: the G allele frequency is approximately 3.3% in Europeans, 5.8% in East Asians, 3.1% in South Asians, and 36.7% in African populations. This high frequency in African populations suggests possible balancing selection, where the variant may confer advantages against certain infections despite increasing autoimmune risk.

Practical Implications

If you carry the G allele, your NF-kB inflammatory pathway has a weakened brake. This means your immune system is predisposed to sustained inflammatory responses that can target your own tissues. The practical value of knowing this genotype lies in targeted monitoring, NF-kB-modulating interventions, and awareness of which autoimmune symptoms to take seriously.

Curcumin (the active compound in turmeric) is one of the most studied natural NF-kB inhibitors. Clinical evidence supports its anti-inflammatory effects¹⁴¹⁴ Clinical evidence supports its anti-inflammatory effects
A capsule combining 150 mg curcumin, 75 mg resveratrol, and 150 mg EGCG reduced TNF-alpha-induced NF-kB activation in healthy volunteers at doses of 500-1,000 mg daily (as bioavailable formulations). Omega-3 fatty acids deserve special attention: the VITAL trial of 25,871 participants¹⁵¹⁵ VITAL trial of 25,871 participants
Randomized, double-blind, placebo-controlled trial over 5.3 years found that vitamin D supplementation reduced autoimmune disease incidence by 22% and omega-3s by 15%, with omega-3 benefits persisting two years after supplementation ended.

Vitamin D optimization is particularly relevant because vitamin D directly modulates NF-kB signaling and T-cell differentiation. For carriers of this variant, maintaining serum 25(OH)D above 40 ng/mL may provide additional immune-regulatory benefit beyond what standard recommendations offer.

Interactions

The TNFAIP3 F127C variant interacts with the broader autoimmune risk landscape. Carriers who also have PTPN22 R620W (rs2476601) face compounded autoimmune susceptibility, as both variants independently impair immune tolerance through different mechanisms — PTPN22 by lowering T-cell activation thresholds, and TNFAIP3 by prolonging NF-kB inflammatory signaling. The combination may be particularly relevant for rheumatoid arthritis and SLE risk.

TLR4 variants (rs4986790) may modulate the effects of impaired A20 function. Since A20 normally terminates NF-kB signaling downstream of TLR4, individuals with both altered TLR4 sensitivity and weakened A20 braking could have amplified or dampened inflammatory responses depending on which TLR4 variant they carry.

NOD2 variants (rs2066844, rs2066845) act in the same bacterial-sensing and NF-kB activation pathway in the gut. A20 normally dampens NF-kB signals triggered by NOD2 activation, so carriers of both NOD2 gain-of-function variants and TNFAIP3 loss-of-function variants may face compounded Crohn's disease risk through excessive intestinal NF-kB activity.

The IL2RA gene¹¹ IL2RA gene
IL2RA encodes CD25, the alpha chain of the high-affinity IL-2 receptor, essential for regulatory T cell (Treg) development and homeostasis harbors multiple independent regulatory variants that together determine how finely tuned your immune system's self-tolerance machinery is. rs2256774 is an intronic variant in IL2RA that operates in the same regulatory neighbourhood as the better-studied rs2104286²² rs2104286
rs2104286 is the index IL2RA MS/T1D risk variant affecting intron-1 methylation and soluble IL-2RA shedding, but contributes an independent signal. Fine-mapping studies of the IL2RA locus in multiple sclerosis have shown that rs2256774 and rs3118470 together provide the best genotype discrimination for MS risk³³ rs2256774 and rs3118470 together provide the best genotype discrimination for MS risk
Babron et al. demonstrated a combined relative risk of 3.54 between least- and most-at-risk genotype combinations at these two SNPs. The same locus has been identified in a genome-wide association study of psoriasis⁴⁴ genome-wide association study of psoriasis
GWAS Catalog GCST, beta=0.068, p=1×10⁻⁹ for psoriasis susceptibility at rs2256774, extending IL2RA's role across skin-directed and systemic autoimmune diseases.

The Mechanism

IL-2 signaling through the high-affinity receptor complex (CD25/CD122/CD132) is the master maintenance signal for Treg viability and function⁵⁵ master maintenance signal for Treg viability and function
IL-2R stimulation drives pSTAT5, which transcribes FoxP3 and anti-apoptotic genes essential for Treg identity and survival. Intronic variants in IL2RA alter the balance between membrane-anchored CD25 — which captures IL-2 for Treg activation — and soluble IL-2RA (sIL-2RA), a shed ectodomain fragment that acts as a decoy receptor⁶⁶ acts as a decoy receptor
sIL-2RA binds IL-2 with moderate affinity, sequestering it in serum and reducing availability for membrane-bound Treg receptors. When sIL-2RA is elevated, Tregs are present in normal numbers but receive insufficient IL-2 stimulation — a functionally hyporeactive state that impairs suppression of autoreactive T cells.

The IL2RA locus demonstrates allelic heterogeneity⁷⁷ allelic heterogeneity
Different variants at the same locus have distinct effects; one allele may preferentially associate with MS, another with T1D, and a third with both diseases. rs2256774 represents one node in this network: its T allele is associated with increased autoimmune susceptibility, while the C allele is protective. The mechanism parallels rs2104286⁸⁸ mechanism parallels rs2104286
rs2104286 alters allele-specific CpG methylation in intron-1, increasing IL2RA transcription and sIL-2RA shedding, though rs2256774 may act through a distinct regulatory element within the same gene.

The psoriasis connection is mechanistically coherent: psoriasis is a T-cell-driven inflammatory skin condition where Treg/Th17 imbalance⁹⁹ Treg/Th17 imbalance
In psoriatic plaques, reduced Treg suppressive capacity allows Th17 and Th1 effector cells to drive IL-17A and TNF-alpha production is a central driver of keratinocyte hyperproliferation. Impaired Treg function from IL2RA variants creates a permissive environment for psoriatic inflammation.

The Evidence

The most direct evidence for rs2256774's clinical relevance comes from two sources. In MS genetics, Babron et al.¹⁰¹⁰ Babron et al.
Babron MC et al. "Determination of the real effect of genes identified in GWAS: the example of IL2RA in multiple sclerosis." EJHG 2012 analysed 26 IL2RA variants in 522 MS trio families and 244 affected sib-pairs, finding that the two-SNP combination of rs2256774 and rs3118470 outperformed any single variant in discriminating case from control genotype distributions (p-corrected=0.009). The relative risk between least and most at-risk genotype combinations reached 3.54 (95% CI: 2.14–5.94) — a substantially larger effect than the modest single-SNP ORs typically observed at GWAS loci, suggesting that rs2256774 and rs3118470 together tag a haplotype with genuine functional consequence.

The 2007 NEJM MS GWAS¹¹¹¹ 2007 NEJM MS GWAS
International Multiple Sclerosis Genetics Consortium. "Risk alleles for multiple sclerosis identified by a genomewide study." NEJM 2007 identified IL2RA as a genome-wide significant MS risk locus (p=2.96×10⁻⁸) in 12,360 subjects, establishing the locus-level evidence that rs2256774 fine-mapping built upon. The psoriasis association (beta=0.068, p=1×10⁻⁹) represents an independent discovery across a different autoimmune phenotype, corroborating IL2RA's role in skin immune dysregulation.

Functional confirmation comes from Cerosaletti et al.¹²¹² Cerosaletti et al.
Cerosaletti K et al. "Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+CD25hi T cells." PLoS One 2013, who showed that IL2RA risk haplotype carriers demonstrate reduced pSTAT5 in CD4+CD25hi T cells despite normal or increased surface CD25, confirming the sIL-2RA shedding mechanism at the cellular level.

Practical Implications

Because rs2256774 modulates the same IL-2R axis as rs2104286, the actionable interventions overlap: strategies that strengthen Treg function through IL-2-independent pathways are particularly relevant for T-risk-allele carriers.

Vitamin D is a key intervention because 1,25-dihydroxyvitamin D3 drives Treg differentiation through VDR/TGF-beta1 signaling, providing a backup pathway when IL-2 access is limited. Omega-3 fatty acids (EPA in particular) reinforce Treg polarization through PPAR-gamma activation while DHA-derived specialized pro-resolving mediators suppress Th17 differentiation — directly countering the Treg/Th17 imbalance that drives psoriatic inflammation.

For psoriasis-specific monitoring, T-allele carriers should pay attention to skin changes suggestive of psoriasis onset — plaques on elbows, knees, scalp, or the lower back — and to triggers that precipitate flares in genetically susceptible individuals (streptococcal infections, certain medications, stress-induced immune dysregulation).

Interactions

rs2256774 operates within the broader IL2RA regulatory network. [Within the locus | Fine-mapping demonstrates at least three partially independent IL2RA signals in autoimmune disease], it acts in combination with rs3118470 and independently from rs2104286, together determining the magnitude of IL-2 signaling attenuation. Carriers of risk alleles at multiple IL2RA SNPs simultaneously may show additive impairment of Treg function.

Cross-locus interactions with CTLA4 rs3087243 are biologically plausible: CTLA4 delivers co-inhibitory signals that complement Treg suppression, and simultaneous impairment of both IL-2R signaling (rs2256774) and CTLA4 co-inhibition (rs3087243) could produce converging Treg dysfunction. These interactions belong in compound action analysis — individual recommendations here address each variant in isolation.

The follicle-stimulating hormone receptor (FSHR) is one of the most important genes in reproductive medicine. Encoded on chromosome 2q16.2 with the gene running on the minus strand, FSHR mediates the action of follicle-stimulating hormone (FSH) in both females — where it drives granulosa cell maturation, folliculogenesis, and ovarian response to exogenous gonadotropin stimulation — and in males, where it supports Sertoli cell function and spermatogenesis. Coding variants in FSHR, particularly rs6165 (Ala307Thr)¹¹ rs6165 (Ala307Thr)
Located in the extracellular hinge region; removes an O-linked glycosylation site and rs6166 (Asn680Ser)²² rs6166 (Asn680Ser)
Located in the intracellular domain; alters cAMP signaling kinetics after FSH binding, are among the most studied pharmacogenomic variants in IVF medicine.

rs2268363 lies in an intron of FSHR at GRCh38 position chr2:48,974,189, approximately 284 base pairs from the closely related intronic variant rs2268361. Its position within the gene means it does not directly alter the FSH receptor protein. Instead, as an intronic tag variant, it may capture information about the underlying haplotype architecture of the FSHR locus — the combination of nearby variants that a given chromosome carries. The G allele occurs at 16% globally, with pronounced ancestry variation: approximately 14% in Europeans, 25% in East Asians, and 42% in African populations.

The Mechanism

As an intronic variant with a CADD score of approximately 11, rs2268363 has no predicted direct functional consequence on the FSH receptor protein. Its biological significance, to the extent it exists, derives from linkage disequilibrium with nearby functional variants across the FSHR locus. The FSHR gene harbors multiple well-characterized regulatory and coding variants — including the promoter SNP rs1394205 (G-29A), which reduces FSHR transcription, and the coding pair rs6165/rs6166 that form the Ala307Thr-Asn680Ser haplotype associated with reduced FSH receptor sensitivity. An intronic variant in close proximity to rs2268361 may partially tag one or more of these haplotypes, particularly in populations where relevant LD patterns are maintained.

The Evidence

The only published genome-wide significant association for rs2268363 is its identification in a 2010 GWAS by Kerns et al.³³ a 2010 GWAS by Kerns et al.
Genome-wide association study to identify SNPs associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys, 2010 as associated with [erectile dysfunction | Inability to achieve or maintain an erection, here specifically as a late adverse effect of pelvic radiation therapy] after radiotherapy for prostate cancer in African-American men (79 patients total; unadjusted p=5.46×10⁻⁸, Bonferroni p=0.028). The investigators proposed that FSHR expression in penile vascular and neural structures might modify radiation sensitivity in these tissues.

This finding was not validated in a subsequent attempt: Schack et al. 2017⁴⁴ Schack et al. 2017
Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. Acta Oncol, 2017 tested rs2268363 among nine radiotherapy-morbidity SNPs in a Danish prostate cancer cohort and could not replicate the original GWAS signal. This is not unusual for GWAS findings from small discovery cohorts — the Kerns 2010 study included only 79 African-American patients, and genomic signals from underpowered studies frequently fail replication.

No direct evidence links rs2268363 specifically to IVF outcomes or ovarian stimulation response. The fertility pharmacogenomics literature on FSHR focuses primarily on rs6165, rs6166, rs1394205, and rs2268361 — all of which are distinct variants. Attributing ART relevance to rs2268363 would require either direct evidence (which is absent) or demonstration of strong linkage disequilibrium with a variant that does have such evidence, which has not been published.

The nearby rs2268361 (284 bp upstream) has been studied in PCOS susceptibility cohorts⁵⁵ cohorts
Saxena et al. 2015, Human Reproduction: rs2268361-T associated with lower FSH levels in European women, P=0.0029 and reproductive phenotypes, but it is a distinct variant and its LD relationship with rs2268363 has not been reported in the published literature.

Practical Implications

For males: the G allele at rs2268363 was associated with a higher risk of erectile dysfunction following pelvic radiotherapy for prostate cancer in one African-American cohort — an association that was not subsequently validated. Men of African ancestry undergoing pelvic radiation therapy may wish to note this result in discussions with radiation oncologists about post-treatment sexual health monitoring, though the evidence does not yet support clinical use of this genotype for decision-making.

For females: there is no published evidence that rs2268363 specifically affects ovarian stimulation response, IVF outcomes, or FSH receptor function in the context of ART. Women who are concerned about their FSH receptor pharmacogenomics profile should prioritize results from rs6165, rs6166, and rs1394205 — the coding and promoter variants with substantial clinical evidence.

The FSHR locus is important for reproductive pharmacogenomics, and rs2268363 is a marker within that locus. As sequencing studies become larger and more ethnically diverse — particularly including African ancestry populations where the G allele is most common — the haplotype contribution of rs2268363 to FSH receptor function may be clarified.

Interactions

rs2268361 (FSHR intronic): The nearest characterized neighbor in FSHR, 284 bp downstream. rs2268361-T is associated with lower basal FSH levels in European women and has been studied in PCOS cohorts across multiple ancestries. The LD relationship between rs2268361 and rs2268363 in different populations has not been characterized in published studies but is likely relevant given their physical proximity.

rs6165 and rs6166 (FSHR coding variants): The primary pharmacogenomic variants at this locus with well-documented effects on ovarian stimulation response in IVF. These coding variants, which form the Ala307Thr-Asn680Ser haplotype, are the actionable variants for ART planning. Their LD relationship with rs2268363 across the full FSHR haplotype block has not been directly reported but is a relevant question for future multi-variant FSHR studies.

rs1394205 (FSHR promoter G-29A): The promoter variant that reduces FSHR transcription; independently studied in additive diplotype analyses alongside rs6165/rs6166. Like rs2268363, it is non-coding, but its mechanistic role (regulating receptor expression level) is established in functional studies.